Treatment of Aggressive Non-Hodgkin’s Lymphoma with Chemotherapy in Combination with Filgrastim

@article{Schriber2002TreatmentOA,
  title={Treatment of Aggressive Non-Hodgkin’s Lymphoma with Chemotherapy in Combination with Filgrastim},
  author={Jeff Schriber},
  journal={Drugs},
  year={2002},
  volume={62},
  pages={33-46}
}
Non-Hodgkin’s lymphoma (NHL) is one of the ten most common cancers in the developed world. The incidence has increased significantly over the past two decades and it is a particular burden in patients over the age of 60 years. The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Haematological growth factors, such as granulocyte colony-stimulating factor (G-CSF), can be used to ameliorate… CONTINUE READING
View on Springer
Alternate Sources

References

Publications referenced by this paper.
SHOWING 1-10 OF 65 REFERENCES

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.

Theresa Hahn, Steven N. Wolff, +6 authors Philip L McCarthy
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2001
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL

High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.

Alessandro Massimo Gianni, Marco Bregni, +9 authors Gianni Bonadonna
  • The New England journal of medicine
  • 1997
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy.

Gerard B. Donnelly, Jill Glassman, +7 authors Carol S. Portlock
  • Leukemia & lymphoma
  • 2000
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

Corinne Haioun, Eric Lepage, +12 authors Félix Reyes
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.

Norbert Schmitz, Peter Dreger, +7 authors Th. Hecht
  • Bone marrow transplantation
  • 1995
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.

William I. Bensinger, Charles H. Weaver, +5 authors C. Dean Buckner
  • Blood
  • 1995
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Comparison of CHOP chemotherapy with autologous bone marrow trans Filgrastim in the Management of NHL 45 © Adis International Limited

LF Verdonck, WL van Putten, A Hagenbeek
  • All rights reserved
  • 2002
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.

James A. Morton, Cheryl Hutchins, Simon Durrant
  • Blood
  • 2001
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

N Schmitz, DC Linch, P Dreger
  • Lancet
  • 1996
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Prognostic factors in non-Hodgkin's lymphoma.

Margaret A Shipp
  • Current opinion in oncology
  • 1992
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL